I'm working in...
Arrow for button
Cross Arrow

I'm working in...

Role
Company
Select

How is the pharmaceutical industry addressing global health inequities?

Katrina Rice, Chief Delivery Officer, Biometrics, eClinical Solutions

The biopharma industry has made efforts to address underrepresentation and diversity in clinical trials, but with slow progress. These included Congress passing legislation in 2022 requiring companies to give the FDA plans for trial diversity and the June 2024 update calling on sponsors to define Diversity Action Plan progress through measurement and monitoring. However, findings from the Government Accountability Office over the past few years showed continued underrepresentation across trial populations, highlighting diversity gaps.

However, regardless of the regulatory landscape, the focus must shift to making material advances in clinical trial diversity as the only path toward scientific accuracy and sound efficacy of medicines. The industry must reexamine how to address this challenge by supporting ‘techquity,’ embracing technology and data infrastructure to operationalize equity across the trial life cycle. Used correctly, and only when placing patients’ experience first, digital health tools can be enablers in connecting data silos, improving patient participation, and building trust within underrepresented communities.

Advancing health equity requires thoughtful embedding of tech and data-enabled approaches within trial strategies and operations. In doing so, the industry will be equipped to achieve the trial diversity objectives, drive equitable research, and ultimately, improve access to care and health outcomes for all.


By submitting, you agree to the processing of your personal data by eClinical Solutions as described in our Privacy Policy.